Research Studies GOTCHA’S By Sally Duffy. Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified.

Slides:



Advertisements
Similar presentations
1 US Investigator Meeting DIAS-4, Chicago, July 2011 Good Clinical Practice (GCP) for Investigators and the Research Team.
Advertisements

CROMS NIDCR Clinical Monitoring
Tips to a Successful Monitoring Visit
Chicken Soup for the Busy Coordinator
Protocol Deviations : Identification, Responses and Solutions The Office of Human Subjects Research’s Compliance Monitoring Program Educational Seminars:
Research Coordination Guidance The Committees on Human Research Serving University of Vermont & Fletcher Allen Health Care
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
MONITORING DIFFERENT TYPES OF TRIALS. BY OGUNDOKUN OLUSEGUN BIOMEDICAL SCIENTIST / CLINICAL RESEARCH PROFESSIONAL BMLS (LAUTECH), PGD (Clin. Research.
Capturing and Reporting Adverse Events in Clinical Research
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Single Subject Protocol Modification Yale Human Research Protection Program * To play the presentation, click on this icon on the status bar below.
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Unlocking the Mystery of General Information Reporting Research Compliance Administration Training Presentation Wednesday, June 6, 2007 Presenter:Heather.
Overview of Good Clinical Practices (GCPs)
M ODULE H I NTERIM M ONITORING V ISIT Denise Thwing 21 Apr Version: Final 21-Apr-2010.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
“So You Think You Know GCP …” Session S794 Jill Matzat, RN, BSN, CCRA, CCRT President, Medical Research Management & CRA Solutions, Inc. Paul Below, CCRA,
Top 10 Medical Device Citations
Janet Ellen Holwell, CCRC, CCRA President, NY Metropolitan Chapter of ACRP.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
ORO Reviews: Frequent Findings Related to IRBs Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight.
Planning and Surviving An Audit/Monitoring visit Carmen B. Jacobs, BS, RN,OCN, CCRP U.T. MD Anderson Cancer Center Houston, Texas U.S.A.
Office of Research Oversight ORO Reporting Adverse Events in Research to ORO Paula Squire Waterman, MS, CIP Department of Veterans Affairs Office of Research.
Sara Brand Associate Director Research Compliance Administration.
Common Audit Findings UTHSC Institutional Review Board (IRB)
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
Adverse Event/Unanticipated Problems Policy and Procedures November 2007.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
1 Denise K. Thwing, MAS, RN, CCRA March 31, 2010 Version: Final 31-Mar-2010.
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
Boehringer Ingelheim Investigator Meeting Study POLO- AML-2 February 23, 2013/Toronto Behbood Sadrolhefazi Therapeutic Area Specialist/ Oncology.
AUDIT REQUIREMENTS, FINDINGS & BASICS RESEARCH COMPLIANCE.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Health Insurance portability and Accountability Act (HIPAA)‏
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Site Monitoring Shirley Frederiksen Donna Harsh.
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
HRPP Policies & Forms Chapter Two Created/Revised for AAHRPP June 1, 2007.
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Sponsor Visits and Monitoring
Patrick Herbison Quality Improvement Specialist Division of Human Subjects Protection DHSP Quality Improvement Activities Including Site Audits, Consent.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Research Documentation Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic Compliance, Corporate Compliance.
Good Clinical Practices and Best Research Practices at MU Health Betty Wilson, CIP, MS Senior Compliance Manager MU IRB Lori Wilcox, EdD Director of Academic.
Session 2 IRB Training  What is the Principal Investigator’s role in Human Subject Research?  What is the role of the Investigator’s staff in Human Subject.
Sponsor Visits and Monitoring Barbara Gallagher, RN Clinical Research Nurse Jefferson Clinical Research Institute.
Supervisory Responsibilities of Clinical Investigators
Governing Body QAPI 2013 Update for ASC
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
The Role and Responsibilities of the Clinical Research Coordinator
How to Handle FDA Audits
Adverse Event Reporting: Trials and Tribulations
Safety of the Subject Cena Jones-Bitterman, MPP, CIP, CCRP
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
ARCADIA Coordinator Webinar
Single Subject Protocol Modification
Quality Control SOP 3.12 Release Date: 08/10/2015.
8 Medication Errors and Prevention.
Event Reporting in Human Subjects Research
Quality Assurance in Clinical Trials
Good clinical practice
Handling of protocol deviations (PDs)
Presentation transcript:

Research Studies GOTCHA’S By Sally Duffy

Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified in protocol Follow-up exams and tests were not performed SAEs and complications were not reported to IRB as required by protocol and IRB Delegated tasks to unqualified individuals Enrolled subjects do not appear to have met eligibility criteria Failed to report to IRB unanticipated problems involving risk to human subjects

Failure to Maintain Complete and Accurate Subject Records 21CFR (a) No source to support data Date discrepancies for tests, administration of study drug Inconsistent weights CRFs do not include information about medications used by subject CRFs incomplete...pages not signed and dated Incorrect serial/model numbers used

Failure to Report to IRB 21CFR (b) and (1) SAE reports given to the FDA and IRB did not match Subject hospitalized and died, however, there is no documentation indicating prompt reporting to IRB UADEs not reported within 10 working days of hearing about event Did not meet IRB’s requirements for notification within three business days of becoming aware of SAE

Assessing your practice: Failure to follow the protocol, investigator agreement or regulations Protocol deviations, with or without sponsor waivers, are reportable deviations Be familiar with protocol requirements. –Print Inclusion/exclusion criteria and evaluate carefully; use as enrollment checklist. –Print study visit schedules and ensure they are followed. Place in front of subject binder and check off at each visit. –Coordinate appointments with other departments

Assessing your practice: Failure to follow the protocol, investigator agreement or regulations When protocol deviations are discovered consider a Root Cause analysis and a Corrective and Preventive Action (CAPA) Plan Evaluate WHY deviation occurred Determine where else it could have occurred Develop and document plan to prevent recurrence Report deviations as required Monitor performance to ensure corrective actions are effective in preventing recurrence

Failure to Maintain Accurate Source Documentation CRF data points must be supported in source documents unless specified otherwise in protocol Source document worksheets may be created to capture data not normally recorded elsewhere CAUTION: If worksheets are used there is a potential for conflicting source data due to capture of redundant data ALWAYS know where the data is first recorded

Assess your Practice Protocol normally defines reporting timelines to the Sponsor SAEs, UADEs and protocol deviations to protect life or physical well-being of a subject in an emergency are normally most urgent. Each IRB has its own policies and procedures –Obtain and understand the SOPs/policies of your IRB. IRBs are required to have written policies

Assessing your Practice Essential to follow through to resolution any outstanding issues/queries –Question recurring issues –Implement corrective actions to prevent recurrence Presentation of source documentation is critical –Patient eligibility requirements as stated in the clinical protocol –Study endpoints –Adverse event details